Evidence map›Paper›PMID 29618841›Full record

Trial reportHypertension research : official journal of the Japanese Society of Hypertension2018

Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.

Kanako Bokuda, Satoshi Morimoto, Yasufumi Seki, Midori Yatabe, Daisuke Watanabe, Junichi Yatabe, Takashi Ando, Satoru Shimizu, Hiroshi Itoh, Atsuhiro Ichihara

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. The (pro)renin receptor in health and disease.Nature reviews. Nephrology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kanako BokudaDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan. kanakobkd@endm.twmu.ac.jp.
Satoshi MorimotoDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Yasufumi SekiDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Midori YatabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Daisuke WatanabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Junichi YatabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Takashi AndoDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Satoru ShimizuDepartment of Medical Education, Tokyo Women's Medical University, Tokyo, Japan.
Hiroshi ItohDepartment of Endocrinology, Metabolism and Nephrology, Keio University, School of Medicine, Tokyo, Japan.
Atsuhiro Ichihara
Tokyo Women's Medical University · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The (pro)renin receptor is important in the regulation of the tissue renin-angiotensin-aldosterone system. The benefits and safety of single-aliskiren treatment without other renin-angiotensin-aldosterone system inhibitors remain unclear. The serum level of the soluble form of the (pro)renin receptor is thought to be a biomarker reflecting the activity of the tissue renin-angiotensin-aldosterone system. We investigated the effects of single renin-angiotensin-aldosterone system blockade with aliskiren on renal and vascular functions and determined if serum level of the soluble (pro)renin receptor was a predictor of aliskiren efficacy in hypertensive patients with chronic kidney disease. Thirty-nine essential hypertensive patients with chronic kidney disease in our outpatient clinic were randomly assigned to receive either aliskiren or amlodipine. The parameters associated with renal and vascular functions and indices of renin-angiotensin-aldosterone system components, including serum levels of the soluble form, were evaluated before and after 12-week and 24-week treatment. Blood pressure was not significantly different between the groups. No significant changes in serum levels were observed in the soluble (pro)renin receptor in either group. Urinary albumin, protein excretion, and cardio-ankle vascular index significantly decreased in the aliskiren group. In the aliskiren group, there was a significant negative correlation between the basal level of the soluble (pro)renin receptor and the change in plasma aldosterone concentration. Single renin-angiotensin-aldosterone system blockade with aliskiren showed renal and vascular protective effects independent of blood pressure reduction. Serum levels of the soluble (pro)renin receptor may indicate aldosterone production via the (pro)renin receptor in the adrenal gland.

Indexed as

AgedAldosteroneAmidesAntihypertensive AgentsBlood PressureFemaleFumaratesHumansHypertensionKidneyKidney Function TestsMaleMiddle AgedProrenin ReceptorReceptors, Cell SurfaceRenal Insufficiency, ChronicAldosteronealiskirenAmidesAntihypertensive AgentsATP6AP2 protein, humanFumaratesProrenin ReceptorReceptors, Cell SurfaceVacuolar Proton-Translocating ATPases

Identifiers

PMID29618841
OpenAlexW2795831384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.